Search PubMed⌕ Search

Biomedical subjects

R Germiniani

Publications and source records attributed to R Germiniani.

At least 37 records · Page 2Linked to original sources
PubMed1986

Effectiveness of defibrotide for prophylaxis of deep venous thrombosis after general surgery: a double-blind, placebo-controlled clinical trial.

The prophylactic activity of defibrotide, a new extractive antithrombotic-thrombolytic agent of mammalian origin, was assessed by detection of deep venous thrombosis (DVT) in patients who underwent general elective surgery. 120 patients (aged 25-85 years, mean 55.6) were randomly assigned to defibrotide (60 patients) or to placebo (60 patients). The two groups were homogeneous for age, sex and risk factors for DVT. The active drug was given intravenously 200 mg four times a day, starting the day before the operation and then for the following 7 days. To detect DVT, 125I-fibrinogen was used, by conventional methods. Defibrotide reduced the frequency of DVT to 4/60 (7%) from 16/60 (27%) in the placebo group. The difference was highly significant (p less than 0.01). Neither side effects nor anticoagulant activity were observed. On the basis of this evidence, defibrotide may be considered an effective and well-tolerated drug for prevention of DVT.

Adult↗
PubMed1985

Effects of buflomedil in a group of patients with chronic peripheral arterial diseases. Clinical and hemorheological evaluation.

Fifty-three patients suffering from chronic arterial diseases of the lower limbs were treated with buflomedil, a vasoactive drug with vasodilating and hemorheological action on the microcirculation. The patients suffered from pain on walking or pain at rest; they were given 300 mg buflomedil orally twice a day for a period of about 2 months. The walking distance before pain onset was checked in all patients before and after the trial. Blood and plasma viscosity, haematocrit and fibrinogen and a Doppler velocimetry were also recorded. A significant improvement of the walking distance before pain onset was observed in nearly all patients, and in most patients the morphology of the velocity waves improved, too. No clear correlation between the positive clinical results and the hemorheological parameters studied could be observed.

Aged↗
PubMed1981

[Intestinal occlusion in colo-rectal cancer].

A comparison was made between 73 patients with colon-rectum neoplasia operated urgently due to occlusion and 85 electively operated in the absence of mechanical ileus. Six parameters were examined: 1) Duration of preoperative symptomatology; 2) Seriousness of preoperative symptomatology; 3) Extention of neoplasia at surgery; 4) Type of operation; 5) Postoperative mortality; 6) Long-term survival. It was found that obstruction often occurs within 5 months after the onset of symptoms and in cases where the tumour is still local (55%). It is attended by higher postoperative mortality (22%) and shorter survival (18 as opposed to 23 months).

Adult↗
PubMed1980

[Combined therapy of colonic and rectal neoplasms in an advanced phase].

The results obtained in a series of 75 patients suffering from advanced cancer of the colon-rectum are examined. Survival of these patients is looked at as a function of the extent of surgical demolition, and as a function of postoperative chemotherapy. Demolition interventions were followed by much higher survival than was observed following palliative operations. At the same time, survival was higher in patients who underwent post-operative chemotherapy. The results therefore justify a more aggressive approach in advanced cancer of the colon-rectum.

Adult↗
PubMed1978

[Kinetics of loss of body weight after intestinal by-pass].

Changes in body weight (absolute and percent), overweight index, and body surface area were examined in 27 grossly obese subjects after jejunal-ileal by-pass. Curves were steeper and linear for 3-4 months and then flattened out for the remainder of the twelve-month period of observation. They were parallel to each other even when a division was made between patients weighing more and less than twice their ideal weight. This shows that if a person weighs more than 120 Kg his weight loss curve will depend on the time that has elapsed since surgery. It is virtually independent of the start value.

Adult↗
PubMed1977

[Chemotherapeutic results in 62 cases of breast cancer in conjunction with several clinical variables].

Alkylating drugs, alkylating drugs + antimetabolites, and alkylating drugs + antimetabolites + Vinblastine were used to treat 62 patients. The results were assessed in terms of Karnofsky's classes and related to the following parameters: age, free interval, menopausal status, results of prior endocrine management, site of dominant metastases, length of survival. 44 failures (71%) and 18 objective responses (29%) were noted. A mean survival of 17.3 months was noted for the entire series. Subjects who failed to respond survived an average of 14 months, as opposed to 25.5 months for the responders. This difference was just significant. No relation could be shown between the results and the other parameters, whereas that between the results and the length of survival was highly significant. It is clear that the variables considered cannot be relied upon in predicting the outcome of chemotherapeutical management. If the latter is effective, however, survival will almost certainly be prolonged.

Adult↗
PubMed1977

[Combination antimetabolite-alkylating agent-vinblastine in the treatment of advanced breast cancer].

The results obtained in 14 patients suffering from hormone-resistant metastatic breast cancer treated with the following association: methotrexate (5-fluorouracyl in case of methotrexate intolerance), cyclophosphamide, vinblastin administered i.v. once every 10-13 days, are reported. 4 objective regression (29%) were observed but survival did not very appreciably differing therapy. In 9 cases (65%) intolerance of various types was observed but in 8 these signs regressed in a short time and the therapy was resumed.

Adult↗